Abstract
Cardiac blood flow is a critical determinant of human health. However, definition of its genetic architecture is limited by the technical challenge of capturing dynamic flow volumes from cardiac imaging at scale. We present DeepFlow, a deep learning system to extract cardiac flow and volumes from phase contrast cardiac magnetic resonance imaging. A mixed linear model applied to 37,967 individuals from the UK Biobank reveals novel genome-wide significant associations across cardiac dynamic flow volumes including aortic forward velocity, total left ventricular stroke volume, forward left ventricular flow and aortic regurgitation fraction. Mendelian randomization using CAUSE reveals a causal role for aortic root size in aortic valve regurgitation. The most significant contributing variants (near ELN, FBN1 and ULK4) are implicated in connective tissue and blood pressure pathways. DeepFlow cardiac flow phenotyping at scale, combined with population-level genotyping data in the UK Biobank, reinforces the contribution of connective tissue genes, blood pressure and root size to aortic valve function in the general population.
Competing Interest Statement
B.M. is part of the Scientifc Advisory Board of Fleischhacker GmbH. E.A. is founder of Personalis, DeepCell, Svexa; advisor to Pacific Biosciences, SequencBio, and Apple and non-executive director of AstraZeneca. J.S. is a Consultant for Google AI. V.P. is SAB for BioMarin and Lexeo Therapeutics; a Consultant for viz.ai and Nuevocor and has sponsored research from Biomarin, Inc. and Saliogen Therapeutics. M.S. receives research support from Siemens Healthineers and GE Healthcare, and is a consultant to medtronic, G3, and Imagion Biosciences. All other authors have no conflicts of interest to declare.
Funding Statement
This study received funding from the Deutsche Forschungsgemeinschaft (DFG-German Research Foundation) under the Walter-Benjamin Program (3196/3-1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank received ethical approval from the National Health Service's National Research Ethics Service North West (11/NW/0382).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
